Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21538189 | 0.92 | ALDH1A1 (0.49) | MAPTMEN1KMT2APDE4AMAPK1 | |
| SCHEMBL8393292 | 0.92 | ALDH1A1 (0.49) | MAPTMEN1KMT2APDE4AMAPK1 | |
| SCHEMBL6036801 | 0.92 | ALDH1A1 (0.49) | MAPTMEN1KMT2APDE4AMAPK1 | |
| SCHEMBL9512889 | 0.92 | ALDH1A1 (0.49) | MAPTMEN1KMT2APDE4AMAPK1 | |
| SCHEMBL13254106 | 0.88 | PDE4A (0.39) | MAPTMEN1KMT2APDE4AMAPK1 | |
| SCHEMBL20647462 | 0.88 | — | — | |
| SCHEMBL6036805 | 0.88 | — | — | |
| SCHEMBL20640349 | 0.88 | — | — | |
| SCHEMBL25686596 | 0.79 | — | — | |
| SCHEMBL6036787 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030129191-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-07-10 | — | — | US | claimed |
| US-5624896-A | Clearing agents useful in pretargeting methods | NEORX CORPORATION (US) | 1997-04-29 | — | — | US | claimed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| US-7060689-B2 | Injection of chemical intermediates into mammalian cells; obtain cells, inject with ligand joined colloid, detect signal from ligand | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-06-13 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-0906015-A4 | LIVER RETENTION CLEARING AGENTS | NEORX CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030129191-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0794788-B1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORP (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020164648-A1 | Injection of chemical intermediates into mammalian cells; obtain cells, inject with ligand joined colloid, detect signal from ligand | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-11-07 | — | — | US | disclosed |
| US-6416738-B1 | ADMINISTERING TO A RECIPIENT A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND A MEMBER OF A LIGAND/ANTI-LIGAND BINDING PAIR, THEREAFTER ADMINISTERING TO THE RECIPIENT A CLEARING AGENT, ADMINISTERING SECOND CONJUGATE | NEORX CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2001005433-A2 | DELIVERY AND RETENTION OF ACTIVITY AGENTS TO LYMPH NODES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-01-25 | — | — | WO | disclosed |
| US-5886143-A | Hepatic-directed compounds and reagents for preparation thereof | NEORX CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1997046099-A1 | LIVER RETENTION CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997046098-A1 | CLUSTER CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5624896-A | Clearing agents useful in pretargeting methods | NEORX CORPORATION (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129191-A1 | Pretargeting methods and compounds | BTD, HLCS, STRA6 | MAPT 2022/4885MEN1 496/4885KMT2A 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.